Vigil Neuroscience, Inc. (VIGL)

NASDAQ: VIGL · Real-Time Price · USD
3.050
+0.010 (0.33%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.33%
Market Cap 120.92M
Revenue (ttm) n/a
Net Income (ttm) -82.60M
Shares Out 39.65M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,993
Open 3.030
Previous Close 3.040
Day's Range 2.944 - 3.090
52-Week Range 2.470 - 6.060
Beta 1.93
Analysts Buy
Price Target 16.80 (+450.82%)
Earnings Date Nov 7, 2024

About VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 69
Stock Exchange NASDAQ
Ticker Symbol VIGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $16.8, which is an increase of 450.82% from the latest price.

Price Target
$16.8
(450.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

2 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

2 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

3 months ago - GlobeNewsWire

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathw...

3 months ago - GlobeNewsWire

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer's disease (AD) -

4 months ago - GlobeNewsWire

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

4 months ago - GlobeNewsWire

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

4 months ago - GlobeNewsWire

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 ag...

5 months ago - GlobeNewsWire

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it ha...

5 months ago - Business Wire

Vigil Neuroscience to Present in Upcoming June Investor Conferences

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of n...

6 months ago - GlobeNewsWire

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of n...

7 months ago - GlobeNewsWire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 –

7 months ago - GlobeNewsWire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology -

7 months ago - GlobeNewsWire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –

8 months ago - GlobeNewsWire

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

8 months ago - GlobeNewsWire

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

9 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

9 months ago - GlobeNewsWire

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favo...

9 months ago - GlobeNewsWire

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS)  and details patients' barriers to genetic testing

9 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

10 months ago - GlobeNewsWire

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 -

11 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

1 year ago - GlobeNewsWire

Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway

Positive interim results reported from phase 2 IGNITE study using iluzanebart for ALSP treatment from 6 patients. Additional results from phase 2 IGNITE study usung iluzanebart for the treatment of pa...

1 year ago - Seeking Alpha

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent wit...

1 year ago - GlobeNewsWire

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molec...

1 year ago - GlobeNewsWire